Skip to content
DataLookout
Menu

NCT02320435

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 110 versions: 37 with changes below, 13 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Primary and study completion pushed from Dec 31, 2026 to Mar 28, 2027
    • Site details revised at 3 of 62 sites
  2. Minor Study sites: 61 to 62v109
  3. Minor Study sites: 59 to 61v108
  4. Minor Study sites: 61 to 59v106
  5. Notable Primary and study completion dates: May 31, 2026 to Dec 31, 2026
    • Study sites: 62 to 61
    v105
Show 32 earlier versionsHide 32 earlier versions
  1. Minor Primary and study completion dates: Dec 31, 2025 to May 31, 2026
    • Study sites revised (62)
    v102
  2. Minor Study sites: 63 to 62v101
  3. Minor Study sites: 62 to 63v100
  4. Minor Site details revised at 1 of 62 sitesv95
  5. Minor Study sites revised (62)v94
  6. Notable Primary and study completion dates: May 31, 2024 to Dec 31, 2025
    • Enrollment target: 153 to 154
    • Study sites revised (62)
    v93
  7. Minor Site details revised at 1 of 62 sitesv92
  8. Minor Study sites: 61 to 62v90
  9. Minor Study sites: 62 to 61v87
  10. Minor Study sites revised (62)v86
  11. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 250 to confirmed 153
    • Study sites: 67 to 62
    v84
  12. Minor Study sites: 68 to 67v83
  13. Minor Study sites: 66 to 68v82
  14. Minor Site details revised at 1 of 66 sitesv81
  15. Minor Study sites: 62 to 66v80
  16. Minor Site details revised at 1 of 62 sitesv79
  17. Minor Site details revised at 1 of 62 sitesv77
  18. Minor Site details revised at 1 of 62 sitesv75
  19. Minor Primary and study completion dates: May 24, 2025 to May 31, 2024v74
  20. Minor Site details revised at 3 of 62 sitesv73
  21. Minor Site details revised at 3 of 62 sitesv72
  22. Minor Study sites revised (62)v71
  23. Minor Study sites revised (62)v70
  24. Minor Interventions: Pertuzumab (Drug) to Other Combination Anti-Cancer Therapies (Drug), Pertuzumab (Drug), Trastuzumab (Drug)
    • Site details revised at 1 of 62 sites
    v69
  25. Minor Site details revised at 3 of 62 sitesv68
  26. Minor Study sites: 60 to 62v67
  27. Minor Study sites: 58 to 60v66
  28. Minor Site details revised at 9 of 58 sitesv65
  29. Minor Site details revised at 6 of 58 sitesv64
  30. Minor Study sites: 56 to 58
    • Primary and study completion dates: Feb 6, 2025 to May 24, 2025
    v63
  31. Minor Study sites: 48 to 56v62
  32. Minor Study sites: 46 to 48v61
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free Survival
Timeframe: From date of first dose of pertuzumab in this study until the date of disease progression or death, whichever occurs first (up to approximately 10 years)
Overall Survival
Timeframe: From date of first dose of pertuzumab in this study until the date of death (up to approximately 10 years)
Number of Participants with Adverse Events by Severity, Classified According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03
Timeframe: From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
Number of Participants with Adverse Events Leading to Pertuzumab Discontinuation or Dose Interruption
Timeframe: From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
Number of Participants with Non-Serious Adverse Events of Special Interest (AESIs)
Timeframe: From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
Left Ventricular Ejection Fraction (LVEF) Over Time
Timeframe: Baseline, every 3 treatment cycles (1 cycle is 21 days), and 28 days after last dose of pertuzumab (up to approximately 10 years)

Arms and interventions

Pertuzumab (Single-Agent or Combination Therapy)Experimental

Pertuzumab will continue to be administered as a single agent or in combination with other anti-cancer therapies at the same dose, schedule, and guidelines that were in effect at the end of the Parent study.

Drugs: Pertuzumab, Trastuzumab, Other Combination Anti-Cancer Therapies

Sites

62 sites in 15 countries

China 9, Brazil 8, Italy 7, Spain 6, Germany 5, France 4, Mexico 4, Portugal 4, Japan 3, Peru 3, South Korea 3, Russia 2, Ukraine 2, Costa Rica 1, Poland 1